Aspirin A Historical and Contemporary Therapeutic Overview

被引：196

作者：

Fuster, Valentin ^{[1
]}

Sweeny, Joseph M. ^{[1
]}

机构：

[1] Mt Sinai Med Ctr, New York, NY 10029 USA

来源：

CIRCULATION | 2011年 / 123卷 / 07期

关键词：

aspirin; cardiovascular disease; history; LOW-DOSE ASPIRIN; ACUTE MYOCARDIAL-INFARCTION; PRIMARY PREVENTION; CARDIOVASCULAR-DISEASE; UNSTABLE ANGINA; RANDOMIZED-TRIAL; EVENTS; ASSOCIATION; INHIBITORS; MECHANISM;

D O I：

10.1161/CIRCULATIONAHA.110.963843

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：768 / 778

页数：11

共 73 条

[1]

[Anonymous], 2009, Drug Ther Bull, V47, P122, DOI 10.1136/dtb.2009.10.0045

[2]

Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71

[3] ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither [J].

Baigent, C ;

Collins, R ;

Appleby, P ;

Parish, S ;

Sleight, P ;

Peto, R .

BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7141) :1337-1343

[4] Acetylation of prostaglandnin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase [J].

Bala, Manju ;

Chin, Cindy N. ;

Logan, Asha T. ;

Amin, Taneem ;

Marnett, Lawrence J. ;

Boutaud, Olivier ;

Oates, John A. .

BIOCHEMICAL PHARMACOLOGY, 2008, 75 (07) :1472-1481

[5] The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease [J].

Belch, Jill ;

MacCuish, Angus ;

Campbell, Iain ;

Cobbe, Stuart ;

Taylor, Roy ;

Prescott, Robin ;

Lee, Robert ;

Bancroft, Jean ;

MacEwan, Shirley ;

Shepherd, James ;

Macfarlane, Peter ;

Morris, Andrew ;

Jung, Roland ;

Kelly, Christopher ;

Connacher, Alan ;

Peden, Norman ;

Jamieson, Andrew ;

Matthews, David ;

Leese, Graeme ;

McKnight, John ;

O'Brien, Iain ;

Semple, Colin ;

Petrie, John ;

Gordon, Derek ;

Pringle, Stuart ;

MacWalter, Ron .

BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 :a1840

[6] Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale [J].

Berg, AO ;

Allan, JD ;

Frame, PS ;

Homer, CJ ;

Johnson, MS ;

Klein, JD ;

Lieu, TA ;

Mulrow, CD ;

Orleans, CT ;

Peipert, JF ;

Pender, NJ ;

Siu, AL ;

Teutsch, SM ;

Westhoff, C ;

Woolf, SH .

ANNALS OF INTERNAL MEDICINE, 2002, 136 (02) :157-160

[7] Aspirin for the primary prevention of cardiovascular events in women and men - A sex-specific meta-analysis of randomized controlled trials [J].

Berger, JS ;

Roncaglioni, MC ;

Avanzini, F ;

Pangrazzi, I ;

Tognoni, G ;

Brown, DL .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (03) :306-313

[8]

Botting RM, 2006, J PHYSIOL PHARMACOL, V57, P113

[9] ASPIRIN, SULFINPYRAZONE, OR BOTH IN UNSTABLE ANGINA - RESULTS OF A CANADIAN MULTICENTER TRIAL [J].

CAIRNS, JA ;

GENT, M ;

SINGER, J ;

FINNIE, KJ ;

FROGGATT, GM ;

HOLDER, DA ;

JABLONSKY, G ;

KOSTUK, WJ ;

MELENDEZ, LJ ;

MYERS, MG ;

SACKETT, DL ;

SEALEY, BJ ;

TANSER, PH .

NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) :1369-1375

[10] Aspirin for the Primary Prevention of Cardiovascular Events A systematic review and meta-analysis comparing patients with and without diabetes [J].

Calvin, Andrew D. ;

Aggarwal, Niti R. ;

Murad, Mohammad Hassan ;

Shi, Qian ;

Elamin, Mohamed B. ;

Geske, Jeffrey B. ;

Fernandez-Balsells, M. Merce ;

Albuquerque, Felipe N. ;

Lampropulos, Julianna F. ;

Erwin, Patricia J. ;

Smith, Steven A. ;

Montori, Victor M. .

DIABETES CARE, 2009, 32 (12) :2300-2306

← 1 2 3 4 5 6 7 8 →